Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.67
+0.09 (1.61%)
At close: Jan 7, 2026, 4:00 PM EST
5.70
+0.03 (0.53%)
After-hours: Jan 7, 2026, 6:52 PM EST
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$598,921
Market Cap
311.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Dec 31, 2020 | 41 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CADL News
- 7 weeks ago - Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 2 months ago - Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - GlobeNewsWire
- 3 months ago - Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - GlobeNewsWire
- 3 months ago - Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PRNewsWire
- 3 months ago - Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - GlobeNewsWire